NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, today announced that two abstracts on the Company’s proprietary lead clinical candidate, Alpha-1 Antitrypsin (AAT), will be presented at the International Conference of the American Thoracic Society, May 15-20 in San Diego, California.
